Kestra Medical Technologies, Ltd. (KMTS)
(Delayed Data from NSDQ)
$14.52 USD
-0.23 (-1.56%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $14.54 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KMTS 14.52 -0.23(-1.56%)
Will KMTS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KMTS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for KMTS
KMTS Board Welcomes New Member Raymond Cohen
RxSight appoints Raymond Cohen to its board of directors
Wells Fargo Maintains Overweight Rating on KMTS, Lowers Price Target | KMTS Stock News
Kestra Medical Technologies Ltd.: Balanced Hold Rating Amid Revenue Growth and EBITDA Challenges
Kestra Stock Slips as Heavy Q4 Loss Overshadows Big Revenue Gains